The CMS proposed PBM transparency rule would require pharmacy benefit managers to disclose compensation, rebates and deal terms to plan sponsors and regulators. Stakeholders say greater transparency could reshape drug pricing by exposing opaque rebate flows and conflicts of interest, potentially lowering costs and altering formulary design. PBMs argue disclosure could reveal proprietary contracting methods, harm competitive negotiating leverage and complicate complex rebate arrangements.
For AI and healthcare, the rule could be transformative: disclosed transaction-level and compensation data would enable machine-learning models to detect pricing anomalies, quantify rebate impacts on net drug costs, and power analytics for plan sponsors, auditors and startups. Conversely, restrictions on data access or redaction of algorithmic details could limit AI-driven auditing, while PBMs and vendors may deploy AI to optimize contracting, raising regulatory and model-interpretability concerns.
